Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GVHD fails the acid test.

Blood·2026
Same author

The PRO-CAR-T™ study: achieving excellence in patient and public involvement and engagement.

Journal of patient-reported outcomes·2026
Same author

Menin inhibitors: a 2-in-1 defense versus AML immune evasion.

Blood·2026
Same author

Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress.

Bone marrow transplantation·2025
Same author

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study.

EClinicalMedicine·2025
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Allogeneic transplantation for lymphoma.

Ronjon Chakraverty1, Stephen Mackinnon

  • 1Department of Haematology, University College London, Pond St, London, NW3 2QG, United Kingdom. r.chakraverty@medsch.ucl.ac.uk

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|April 13, 2011
PubMed
Summary
This summary is machine-generated.

Reduced-intensity allogeneic stem-cell transplantation offers a less toxic option for lymphoma patients. While graft-versus-lymphoma effects show promise, pre-transplant disease status is key for successful outcomes.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Jun 2, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Standard myeloablative allogeneic stem-cell transplantation was limited to young, fit lymphoma patients due to high mortality.
  • Reduced-intensity protocols have increased accessibility by lowering toxicity and mortality rates.

Purpose of the Study:

  • To review the efficacy and challenges of reduced-intensity allogeneic stem-cell transplantation for lymphoma.
  • To identify predictors of outcome and long-term toxicities.

Main Methods:

  • Review of existing literature on reduced-intensity allogeneic stem-cell transplantation in lymphoma patients.
  • Analysis of outcomes, focusing on graft-versus-lymphoma effects and toxicity.

Main Results:

  • Reduced-intensity protocols demonstrate lower toxicity and mortality compared to myeloablative approaches.
  • Pre-transplantation disease status is the most critical factor predicting patient outcomes.
  • Chronic graft-versus-host disease remains a significant long-term toxicity for a subset of survivors.

Conclusions:

  • Reduced-intensity allogeneic stem-cell transplantation is a viable option for selected lymphoma patients, offering improved safety profiles.
  • Further risk-adapted trials are needed to define the optimal role of this therapy, especially for patients with poor prognoses.
  • Graft-versus-lymphoma effects are beneficial, but careful patient selection based on disease status is crucial for maximizing therapeutic benefit.